Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244777 | 0.94 | RXRA (0.46) | CA2CA12CA1CA3TYR | |
| SCHEMBL2248329 | 0.88 | ESR2 (0.53) | ESR2ESR1ALDH1A1APPCYP2C9 | |
| SCHEMBL12893332 | 0.85 | ESR2 (0.47) | ESR2ESR1CYP2C9 | |
| SCHEMBL1256648 | 0.85 | ESR2 (0.47) | ESR2ESR1CYP2C9 | |
| SCHEMBL2246594 | 0.85 | RXRA (0.39) | DRD1SRD5A2RXRATP53TSHR | |
| SCHEMBL2246402 | 0.84 | RXRA (0.41) | CA2CA12CA1CA7CA9 | |
| SCHEMBL2250158 | 0.84 | CA1 (0.51) | CA2CA12CA1CA7CA9 | |
| SCHEMBL1255425 | 0.82 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL14260542 | 0.82 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL2251874 | 0.81 | AURKA (0.47) | RXRATSHRALDH1A1PDE5AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | CA2 1288/4885CA12 1857/4885CA1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.